Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.39 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10005056 | 0.74 | HSPA8 (0.41) | ADKFBP1HSPA8ADORA3AHCY | |
| SCHEMBL2197504 | 0.73 | CDK1 (0.48) | ADKHSPA8ADORA3ADORA2AADORA2B | |
| SCHEMBL11043640 | 0.71 | HSPA8 (0.39) | ADKFBP1HSPA8ADORA3 | |
| SCHEMBL7110520 | 0.71 | SARS1 (0.43) | ADKFBP1HSPA8 | |
| SCHEMBL11165275 | 0.70 | HSPA8 (0.38) | ADKFBP1HSPA8ADORA3 | |
| SCHEMBL11041141 | 0.69 | HSPA8 (0.37) | ADKFBP1HSPA8 | |
| SCHEMBL11042514 | 0.68 | HSPA8 (0.37) | ADKFBP1HSPA8 | |
| SCHEMBL11040775 | 0.68 | SRM (0.37) | ADKFBP1HSPA8 | |
| SCHEMBL11040836 | 0.68 | SRM (0.37) | ADKFBP1HSPA8 | |
| SCHEMBL11310700 | 0.68 | HSPA8 (0.36) | ADKFBP1HSPA8ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219518-A2 | BIOCONJUGATES OF HETEROCYCLIC COMPOUNDS | Taizhou Huifeng Hetai Biotechnology Co. Ltd (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-3337804-A1 | BIOCONJUGATES OF HETEROCYCLIC COMPOUNDS | Arthus Biosystems LLC (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2016164504-A1 | BIOCONJUGATES OF HETEROCYCLIC COMPOUNDS | ARTHUS BIOSYSTEMS LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-8344115-B2 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | HAO, XIUJUAN | 2013-01-01 | — | — | US | disclosed |
| WO-2009131643-A1 | IMMUNOASSAY FOR SPECIFIC DETERMINATION OF S-ADENOSYMETHIONINE AND ANALOGS THEREOF IN BIOLOGICAL SAMPLES | MONABIO, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090263879-A1 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | HAO, XIUJUAN | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263879-A1 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | AHCY, MAT2A, MAT1A | ADK 310/4885FBP1 485/4885HSPA8 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.